Additionally, four systematic reviews and meta-analyses suggest that SGLT2 inhibitors were associated with reduced mortality and lower COVID-19-related adverse outcomes, whilst one review did not [63–67]. This evidence concerns the gene SLC5A2 and COVID-19.